Meet Our Board of Directors

Our Board of Directors has diverse experience in biotechnology, diagnostics, therapeutics, medical and other industries, bringing decades of experience to the team.

Matt Posard


Mr. Posard brings over 30 years experience of general management and commercialization experience in the biotechnology and diagnostics industry. His expertise is introducing novel and transformational products to medical and research markets while scaling organizations efficiently. Mr. Posard has held executive title responsibilities with several highly successful growth companies including Illumina, Biosite and Gen-Probe. From 2006 to 2015, he held executive positions at Illumina as its VP of Marketing, VP Global Sales and then as Senior VP, General Manager of its Translational and Consumer Genomics and New and Emerging Markets business units. Mr. Posard currently serves on multiple boards including Halozyme Therapeutics (NASDAQ: HALO), Talis Biomedical (NASDAQ: TLIS), and Stemson Therapeutic and as Chairman of the Board of Nautilus Biotechnology. He holds a bachelor’s degree in management science from UC San Diego.

Cynthia Collins

Cynthia Collins has served on our board of directors since the completion of the Business Combination in August 2019 and on DermTech Operations’ board of directors between July 2018 and August 2019. Ms. Collins is the Chief Executive Officer of Editas Medicine (NASDAQ:EDIT) and served as Chief Executive Officer of Human Longevity Inc. from January 2017 to December 2017. From October 2013 to December 2016, Ms. Collins served as the Chief Executive Officer/General Manager of General Electric’s Healthcare Cell Therapy and Lab Businesses and GE’s Clarient Diagnostics. Prior to GE, Ms. Collins served as CEO of GenVec (NASDAQ:GNVC), a vaccine and gene therapy company and before that, she served as Group Vice President, Cellular Analysis Business of Beckman Coulter with responsibility for its Hematology, Flow Cytometry, and Hemostasis businesses. Prior to Beckman Coulter, she served as CEO of Sequoia Pharmaceuticals, Inc., a company developing HIV and HCV therapeutics. Ms. Collins received her BS degree in Microbiology from the University of Illinois, Urbana and her MBA from The University of Chicago Booth School of Business. Ms. Collins is a member of the board of directors of Editas Medicine, ARM Foundation for Cell and Gene Medicine, Triumvira Immunologics, and Biocare Medical. Ms. Collins is qualified to serve on our board of directors because of her broad experience serving as the chief executive officer for a variety of companies in the life sciences industry and her experience serving on numerous boards of directors.

John Dobak, M.D.

President and CEO

John Dobak, M.D., has served as Founder and CEO of several venture-backed life science companies in San Diego. Dr. Dobak is the President of the JAKK Group, a life sciences technology accelerator, which has created several companies, including Lithera, INNERCOOL Therapies, and CryoGen/CryoCor. These companies have developed and marketed therapeutics, ranging from endovascular hypothermia to treat cardiac arrest to catheter-based treatments for cardiac arrhythmias. They have been financed by top tier investment firms and have achieved exits through acquisition and an IPO. Dr. Dobak and these companies are the recipients of several awards for entrepreneurship and innovation, including UCSD Connect’s Most Innovative New Product and MIT’s TR 100. Dr. Dobak received a bachelor’s degree from UCLA and a medical doctorate from UCSD. 

Gary Jacobs

Mr. Gary Jacobs is Founder and Managing Director of Jacobs Investment Company LLC (JIC), a diverse international portfolio which includes impact investing in Israel. In addition, he is a General Partner in NGT3, a technological incubator in Nazareth, focusing on Israeli Arab entrepreneurs. Mr. Jacobs is also actively involved with education and philanthropy, serving as Chairman of the Board of Trustees of High Tech High in San Diego. Mr. Jacobs is a member of the University of California, San Diego Athletic Board; UC San Diego Foundation Board; and is Chair of the Dean’s Advisory Council for Social Sciences at UC San Diego. Mr. Jacobs also serves on numerous public and private corporate boards. Mr. Jacobs received his bachelor’s degree in management science from the University of California, San Diego.

Scott R. Pancoast

Mr. Pancoast has been CEO & Founder of Zylö Therapeutics since 2017. Previously, he was with biotech startup Lpath, Inc., where he served on the board from 1998 through 2014 and served as President and CEO from 2004 through 2014, taking it public in late 2005 [Nasdaq:LPTN]. Prior to joining Lpath, from 1994 to 2004, Mr. Pancoast was the Executive Vice President of venture-capital investor Western States Investment Corporation (WSIC), where he served as Executive Chairman for several established companies and invested—on WSIC’s behalf—in over a dozen technology start-ups. He has served as the CEO or interim CEO for eight start-up companies and has been a board member for over 15 companies, including four public ones. He earned an MBA from Harvard and a B.A. (economics) from the University of Virginia. Mr. Pancoast’s qualifications to sit on our Board include his experience as a venture capitalist and business leader, his current and past service as a DermTech board member, and his current and past service as a board member for public and private companies.

Enrico Picozza

Enrico Picozza is a partner of HLM Venture Partners, a venture firm that invests in tech-enabled healthcare services, healthcare information technology, and medical device and diagnostics companies. He is also currently a director of AbleTo, mPulseMobile, RubiconMD and a board observer to OnShift. His previous board appointments included Vericare (sold to MedOptions), Spinal Kenetics (sold to Orthofix), Transend Medical (sold to Alcon), Medicalis (sold to Siemens), Aventura (sold to Philips), SensAble Technologies (sold to 3D Systems) and was a board observer and special advisor to Interlace Medical (sold to Hologic), and Tandem Diabetes (NASDAQ). Prior to joining HLM as a Venture Partner, Enrico co-founded HTS Biosystems, Inc., an early developer of platforms for drug discovery and point of care diagnostics, where he served as Chief Operating Officer and Chief Technology Officer. Prior to HTS, Enrico held leadership positions with PerkinElmer, Inc. and Applied Biosystems, Inc. Enrico was part of the startup team within Perkin Elmer involved in the development and commercialization of PCR, the revolutionary DNA-replicating technology that enabled the development of some of the most significant advancements in molecular biology. Enrico is the holder of nine patents and has been recognized by the Smithsonian Institute for his achievements in PCR. He is the author of numerous scientific papers and has been a frequent international speaker. Enrico attended the University of Connecticut for undergraduate and postgraduate studies in the major Molecular and Cell Biology.

Herm Rosenman

Herm Rosenman brings more than 30 years of public company operating and financial experience. Mr. Rosenman has served as a member of the board of directors of Natera, Inc. since 2017, and as its CFO from 2014 to 2017. Prior to that, he was the SVP of finance and CFO of Gen-Probe Inc., where he was instrumental in its 2002 IPO and its 2012 sale to Hologic Inc. Prior to joining Gen-Probe, Mr. Rosenman was president and CEO of Ultra Acquisition Corp., a retail chain and consumer products manufacturer, and president and CEO of RadNet Management Inc., a large healthcare provider. From 2012 to 2014, Mr. Rosenman focused on his board memberships. He has served on the board of directors of Oxford Immunotec Global PLC, a commercial-stage diagnostics company, since 2013, and of Vivus, Inc., a biopharmaceutical company, also since 2013. Mr. Rosenman also previously served on the board of directors of BioFire Diagnostics, Medistem, Inc., a stem cell therapy company, ARYx Therapeutics Inc., a private drug discovery and development company, Infinity Pharmaceuticals, Inc., a drug discovery and development company, and several privately held companies. Mr. Rosenman holds a BBA in accounting and finance from Pace University and an MBA in finance from the Wharton School of the University of Pennsylvania.